GENETWORx Certified To Perform Pharmacogenetic Testing In NY
Monday, September 8, 2014
Richmond-area laboratory GENETWORx has obtained certification to perform its DNA Drug-Response genetic testing on samples collected from patients in the state of New York. The laboratory will begin performing its pharmacogenetic testing panel that includes assays for drug metabolizing enzymes and cardiac disease risk factors for physicians in New York State, one of the largest markets for pharmacogenetic testing in the United States.
GENETWORx CEO William Miller explained, "The New York State certification demonstrates our commitment to provide the highest quality laboratory services, and gives us a competitive edge over laboratories that are not certified in New York State."
GENETWORx Laboratory Director, Sarah Jacobs-Helber, PhD, HCLD (ABB) added, "The addition of New York State certification completes our state and federal licensure process and allows GENETWORx to provide services to patients in all states. We are proud of the team we have put together and look forward to providing our unique brand of services to the citizens of New York."
The GENETWORx DNA Drug-Response Panel examines a patient's genetic metabolizer type for several of the most important Cytochrome P450 (CYP) enzymes that activate many commonly prescribed drugs for cardiology, pain management and psychiatry.